330 related articles for article (PubMed ID: 25811445)
21. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.
Liu J; Dong M; Sun X; Li W; Xing L; Yu J
PLoS One; 2016; 11(1):e0146195. PubMed ID: 26727114
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
[TBL] [Abstract][Full Text] [Related]
23. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
25. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
26. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
27. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
28. Influence of Body Mass Index on the Prognostic Value of Tumor ¹⁸F-FDG Uptake in Stage I Non-Small Cell Lung Cancer.
Hyun SH; Lee KH; Choi JY; Kim BT; Kim J; Zo JI; Kim H; Kwon OJ; Ahn HK
PLoS One; 2015; 10(12):e0145020. PubMed ID: 26684001
[TBL] [Abstract][Full Text] [Related]
29. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
Nair VS; Barnett PG; Ananth L; Gould MK;
Chest; 2010 May; 137(5):1150-6. PubMed ID: 20038738
[TBL] [Abstract][Full Text] [Related]
30. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
31. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
[TBL] [Abstract][Full Text] [Related]
32. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
Lee JW; Na JO; Kang DY; Lee SY; Lee SM
Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
[TBL] [Abstract][Full Text] [Related]
36. Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma.
Duan XY; Wang W; Li M; Li Y; Guo YM
Braz J Med Biol Res; 2015 Mar; 48(3):267-72. PubMed ID: 25651460
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Tanaka H; Hayashi S; Hoshi H
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
[TBL] [Abstract][Full Text] [Related]
38. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
40. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]